Cargando…

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells

BACKGROUND: For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Jin, Wang, Xue, Qu, Jun, Mager, Donald E., Straubinger, Robert M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583190/ https://www.ncbi.nlm.nih.gov/pubmed/33097020 http://dx.doi.org/10.1186/s12885-020-07398-9

Ejemplares similares

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Multi‐Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
por: Miao, Xin, et al.
Publicado: (2016)

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
por: Fichtner, Michael, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo
por: Morrish, Emma, et al.
Publicado: (2020)

NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP
por: Zhao, Li, et al.
Publicado: (2017)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma
por: Ramakrishnan, Vidya, et al.
Publicado: (2018)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021)

Synergistic Effects of Apigenin and Paclitaxel on Apoptosis of Cancer Cells
por: Xu, Yimiao, et al.
Publicado: (2011)

SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway
por: Ding, Jun, et al.
Publicado: (2020)

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
por: Zakaria, Z, et al.
Publicado: (2016)

Editorial Expression of Concern: birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2018)

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
por: Jiménez-Guerrero, Rocío, et al.
Publicado: (2018)

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death
por: Vetma, Vesna, et al.
Publicado: (2017)

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
por: O'Reilly, Eileen M., et al.
Publicado: (2017)

Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3‐Hour Infusion of Paclitaxel
por: Minami, Hironobu, et al.
Publicado: (2001)

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells
por: Wang, Chihuei, et al.
Publicado: (2015)

Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
por: Wang, Jun, et al.
Publicado: (2020)

Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models
por: Chen, Chunli, et al.
Publicado: (2017)

Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
por: Han, Ernest S., et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014)

Praziquantel Synergistically Enhances Paclitaxel Efficacy to Inhibit Cancer Cell Growth
por: Wu, Zhen Hua, et al.
Publicado: (2012)

Synergistic effects of flavonoids and paclitaxel in cancer treatment: a systematic review
por: Asnaashari, Solmaz, et al.
Publicado: (2023)

Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice
por: Meng, Huan, et al.
Publicado: (2015)

Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice
por: Jiang, Xi-Ling, et al.
Publicado: (2016)

Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
por: Zhang, Xin, et al.
Publicado: (2022)

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
por: Greene, Michelle K., et al.
Publicado: (2020)

Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines
por: Effendi, Wiwin Is, et al.
Publicado: (2019)

Correction to Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice
por: Meng, Huan, et al.
Publicado: (2016)

Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Wang, Jin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_55rmas1llm9f0s8g1pijd47f66